Eli Lilly's Alzheimer's contender Kisunla gets thumbs-down from EU regulators over safety concerns
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease med Kisunla also got a rejection from EU regulators.
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease med Kisunla also got a rejection from EU regulators.
